

Remarks


The claims have been amended to define a method and formulation for using glycosaminoglycan-degrading enzymes to reduce a cell proliferative response. Support for these amendments is found in the specification on at least page 3, lines 20-23; page 6, lines 8-13; page 8, lines 24-27; and the paragraph bridging pages 11 and 12.

Claim 18 has been amended to define a reduction in collagen synthesis. Support for this amendment is found on page 7, lines 4-5 of the specification.

Claim 19 has been amended to define a formulation for systemic administration. Support for this amendment is found in the specification on page 9, lines 16-27.

Examination of claims 1-19 is respectfully solicited.

Respectfully submitted,



Zhaoyang Li
Reg. No. 46,872

Date: July 18, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8473
(404) 817-8588 (Fax)